Last updated:
December 08, 2014
* Perinatal data are the Perinatal Data Page
** Pediatric data are in
the Pediatric Data Page
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
4th
International AIDS Society (IAS) Conference on HIV
Pathogenesis, Treatment and Prevention |
A randomised study to evaluate injection site reactions (ISR)
using three different mechanisms
for delivery of enfuvirtide (ENF): a 27-gauge needle, a 31-gauge
needle and a needle-free device
Boyd M, Truman M, Hales G, et al
Abstract
Recovery of anti-JCV specific T cell responses and better survival
on intensified antiretroviral
therapy in HIV-1 infected patients with progressive multifocal
leukoencephalopathy: the ANRS 125
trial
Gasnault J, Hendel Chavez H, Darasteanu I, et al
Abstract
The prevalence of resistant mutations to enfuvirtide in
antiretroviral naive HIV-1 infected
patients
Chew CB, Shah M, Wang B, Shaw CO, et al
Abstract
French observatory of HIV-1 infected patients experiencing
virological failure while receiving enfuvirtide
salvage antiretroviral therapy containing regimen
Descamps D, Assoumou L, Masquelier B, et al
Abstract
-
Effects
of a NRTI, Stavudine, on Insulin Sensitivity and Mitochondrial Function in
Muscle of Healthy Adults
A Fleischman, S Johnsen, D
Systrom, et al
Abstract
-
Tenofovir Resistance among HIV-infected Patients Failing a Fixed-dose
Combination of Stavudine +
Lamivudine + Nevirapine in a Resource-limited Setting
S Sungkanuparph, W Manosuthi,
S Kiertiburanakul, et al
Abstract
-
Development of Drug Resistance in a Sub-Saharan Cohort of HIV 1-infected
Adult Patients Receiving
Fixed-dose Combination of Stavudine + Lamivudine + Nevirapine as Standard
First-line Regimen
AG Marcelin, B Jarrousse, M
Ba, et al
Abstract
-
POSTER
Severe Hyperlactatemia
Complicating ART with Stavudine First-line Therapy in South Africa:
Incidence,
Risk Factors, and Outcomes
M Osler, D Stead, K Rebe, et al
PDF Poster
Abstract
XVI
International AIDS Conference
|
Abstract
First
line standard antiretroviral therapy (stavudine+lamivudine+nevirapine), a good
or a bad option
for
non-naïve AIDS patients previously exposed to NRTI and/or NNRTI?
Carillo de Casas E., Alonso E., Boon A.
Abstract
Changes
in adipose tissue mitochondrial DNA quality and quantity - relation to HIV
disease,
lipoatrophy and exposure to stavudine
Mallon P, Sedwell R, Duarte N, et al
Abstract
A
history of stavudine (d4T) predicts high HOMA index three years after ART start
Koppel K, Lund B, Sandström E. et al
Abstract
Stavudine or didanosine use, low-level transaminitis (LLT) and hepatic steatosis
in a cohort of
HIV
mono-infected subjects
Bongiovanni M, Smith C, Bhagani S, et al
Abstract
Characteristics and outcomes of patients with symptomatic hyperlactatemia, on a
first-line
antiretroviral regimen of stavudine, lamivudine and nevirapine (D4T/3TC/NVP) in
an urban district
hospital setting in Kenya
Kimani DK., Filén F., Nderitu M., et al
Abstract
Effectiveness and safety of stavudine (d4T) + tenofovir (TDF) backbone as rescue
therapeutic
strategy for HIV-infected patients - GPT study
Pedrol E., Pascual A., Ribera E., et al
Abstract
Effects
of antiretroviral drugs: stavudine, lamivudine and Nevirapine on CD4+ count and
viral
load in
HIV-1 patients attending Jos University Teaching Hospital, Jos Plateau State,
Nigeria
Mu'azu M., Monday D., Bitrus B., et al
Abstract
|
Uridine prevents and treats the lipoatrophic phenotype of adipocytes exposed
to stavudine,
zalcitabine and zidovudine.
Walker U.A., Auclair M, Lebrecht D, et al
Abstract
.
A
randomized study comparing the efficacy and tolerability of low-dose versus
standard-dose
stavudine in antiretroviral-naïve patients (ETOX Study)
Ribera E., Paradiñeiro J.C., Domingo p, et al
Abstract
Effects of Antiretroviral Drugs Stavudine, Lamivudine and Nevirapine on CD4+
count and
Viral Load In HIV-1 Patients attending Jos university Teaching Hospital, Jos
Plateau State,
Nigeria.
Mu'azu M.
Abstract
76
weeks study of safety and efficacy of a simplified fixed-dose combination of
stavudine,
lamivudine and nevirapine (GPO-VIR) for the treatment of advanced
HIV-infected patients.
Anekthananon T., Ratanasuwan W., Techasathit W, et al
Abstract
Preadipocyte differentiation determines the susceptibility to stavudine and
zidovudine-
mediated mitochondrial DNA depletion.
Stankov M., Schmidt R., Behrens G.
Abstract
Long
Term Use of Low dose Stavudine is Effective and Well Tolerated
Urbina A., Jibilian A., Nibbe Y. et al
Abstract
Community-based Generic Antiretroviral Therapy following Single-dose Nevirapine
or
Short-course AZT in Zimbabwe
LZijenah , G Kadzirange, S
Rusakaniko, et al
 PDF
Poster
Abstract
POSTER
In vivo
Determination of Stavudine Activity in the Presence of TAM
F Maggiolo A Callegaro, D Ripamonti, et al
PDF Poster
Abstract
A
Randomized Comparison between Abacavir and Stavudine, both Combined with
Lamivudine/Efavirenz, in Antiretroviral-Naive Patients. Final 96-Week Results
of the
ABCDE
Study
D Podzamczer , E Ferrer , P Sanchez, et
al
Abstract
A Randomized Open Study Comparing the Effect of Reducing Stavudine Dose
vs Switching
to Tenofovir on Mitochondrial Function, Metabolic Parameters, and
Subcutaneous Fat in
HIV-infected Patients Receiving Antiretroviral Therapy Containing
Stavudine
A Milinkovic, S Lopez, S Vidal, et al
Abstract
Similar Incidence of Osteopenia and Osteoporosis in ART-naïve
Patients Treated with
Tenofovir DF or Stavudine in Combination with Lamivudine and
Efavirenz over 144 Weeks
W Powderly, C Cohen, J Gallant,
et al
Abstract
-
POSTER
Stavudine Extended Release Formulation and Tenofovir Disoproxil Fumarate:
Lack
of a Pharmacokinetic
Drug Interaction
S Kaul, K Bassi, B Damle, et al
PDF
Poster 
Abstract
-
POSTER
Baseline Genotype as a Predictor of Virological Failure in Patients
Receiving
Emtricitabine Once Daily
or Stavudine Twice Daily in Combination with
Didanosine
and Efavirenz
K Borroto-Esoda, J Harris, J Waters, et al.
PDF Poster
Abstract
-
POSTER
Lipid
Abnormalities and Body Habitus in a Double-blind, Randomized, Controlled Trial
Comparing
Emtricitabine to Stavudine in HIV+ ART-naive Patients
W Powderly, P Cahn, F Raffi, et al
PDF
Poster
Abstract
-
POSTER
Stavudine
Extended Release Formulation and Tenofovir Disoproxil Fumarate: Lack of
a
Pharmacokinetic
Drug Interaction
S Kau, K Bassi, B Damle,
et al
PDF
Poster
Abstract
-
POSTER
Partial Improvement of
Mitochondrial Dysfunction 48 weeks after Replacement of Stavudine
with either
Abacavir or Zidovudine
G McComsey, C Hoppel, V
Williams,
et al
PDF
Poster
Abstract
-
POSTER
Determinants of Hyperlipidemia in ART-naive Subjects Treated with
Trizivir, Combivir/Nelfinavir,
or
Stavudine/Lamivudine
P Kumar, V
Williams, K Tahima, et al
PDF
Poster
Abstract
|
-
LONG-TERM EVALUATION OF D4T, DDI AND EFV IN ANTIRETROVIRAL NAIVE PATIENTS IN
SENEGAL. ANRS 12-06/IMEA 012 TRIAL
A Canestri, A Ndir,
M Vray, et al
-
EFFECT OF TENOFOVIR (TDF), STAVUDINE (D4T), AND ZIDOVUDINE (ZDV) ON ADIPOCYTE
FUNCTION
OP Flint, R Mulvey,
C Elosua, et al
Abstract
-
QUANTITATION OF INTRACELLULAR d4T-TP AND dT-TP IN HIV-INFECTED SUBJECTS
USING HPLC-MS/MS
R Garcia,
M. Melendez, R Blanco, et al
Abstract
CHARACTERIZATION OF VIROLOGIC FAILURE THROUGH 96 WEEKS AMONG TREATMENT-
NAIVE PATIENTS TAKING TENOFOVIR DF (TDF) OR STAVUDINE (D4T) IN COMBINATION
WITH LAMIVUDINE (3TC) AND EFAVIRENZ (EFV)
MD Miller, NA Margot, DJ McColl, et al
Abstract
|
4th
IAS Conference
XV
International AIDS Conference
11th
CROI
1st
European HIV Drug Resistance Workshop
